Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma

Introduction

B cell maturation antigen (BCMA) or TNFRSF17 is a member of the tumor necrosis factor receptor superfamily with an important role in B cell survival and near ubiquitous expression in plasma cells, including in MM [1]. BCMA is also a relevant immunotherapy target in MM, validated by the therapeutic success of bispecific T cell engaging antibodies [2, 3], chimeric antigen receptor T cells (CAR T) [4, 5], and antibody-drug conjugates [6].

Autologous BCMA-directed CAR T cells have yielded very high rates of treatment response and durable disease control with the advantage of long treatment-free intervals. Two products, idecabtagene vicleucel (ide-cel) [4] and ciltacabtagene autoleucel (cilta-cel) [5], have obtained regulatory approval in some countries for patients with RRMM who have been exposed to prior therapies.

The existing commercial CAR T cell manufacturing processes have some important limitations. The manufacturing time of several weeks leads to the necessity of bridging therapy in many patients, with approximately 10% attrition between apheresis and infusion of cellular product. Cytokine release syndrome (CRS) is common and can be life-threatening in a small proportion of patients. Immune-effector cells associated neurotoxicity syndrome (ICANS) and non-ICANS neurotoxicity occur in < 20% but may cause short and/or long-term disability. Cytopenias are often prolonged and require intense management. Moreover, relapses appear unavoidable. There is therefore a need to optimize the manufacturing process and improve the safety and efficacy of autologous BCMA-directed CAR T cell therapies in order to expand access of these therapies and improve outcomes. CAR T therapy phenotypic attributes, such as enrichment for naïve early memory T cell subtypes, have been previously associated with improved clinical outcomes [7,8,9].

Here we report the results of a phase 1 clinical trial of BMS-986354, an autologous BCMA CAR T cell manufactured using the NEX-T® process, aiming to optimize phenotypic attributes, shorten manufacture time and yield myeloma control with favorable safety profile.

Methods

BMS-986354 contains the same CAR construct present in orva-cel, with an anti-BCMA domain, a CD8 transmembrane domain, 4-1BB costimulatory domain and CD3-z signaling domain [10], but BMS-986354 is manufactured using the proprietary NEX-T® process. The manufacturing process involves selection of CD8+ and CD4 + T cells from the processed apheresis material followed by activation in cytokine enriched culture media. The activated T cells are transduced with BCMA lentivirus and are minimally expanded until harvest, followed by formulation and cryopreservation. The harvest duration leveraging shortened ex-vivo expansion for the NEX-T® process was determined by balancing robustness of the CAR expression and increased proportion of less differentiated T cells that demonstrated increased in vitro proliferative potential and cytolytic activity.

Study design

This was a phase I, multi-center, open label study, performed in two parts consisting of dose escalation and dose expansion. The primary objectives were to evaluate safety and tolerability of increasing doses of BMS-986354 and obtain the recommended phase 2 dose (RP2D). The secondary and exploratory objectives were to evaluate safety, pharmacokinetic (PK) and preliminary efficacy at the RP2D dose based on overall response rate (ORR) and rates of CR/sCR according to the International Myeloma Working Group (IMWG) response criteria [11]. In addition, planned exploratory analysis also included and pharmacodynamic (PD) profile including immunophenotypic characterization of BMS-986354 clinical drug product performance.

In Part A, 3 dose levels (DL) of BMS-986354 were investigated: 20 (DL1), 40 (DL2) and 80 (DL3) x 106 CAR + T cells. At each DL, the study intended to treat a minimum of 3 participants monitored for at least 28 days prior to adjudication of the safety profile of the respective DL. Dose escalation and de-escalation was determined by a Bayesian modified Toxicity Probability Interval 2 (mTPI-2) [12] algorithm with a target dose limiting toxicity (DLT) rate of 30% and an equivalence interval of 25% to 35%.

Participants were 18 years of age or older, had diagnosis of RRMM with confirmed progression during or within 12 months of last therapy or with no response and confirmed progression within the previous 6 months to most recent anti-myeloma treatment. Participants were required to have prior treatment with at least 3 distinct regimens, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), an anti-CD38 monoclonal antibody and prior autologous stem cell transplantation (ASCT) unless ineligible. They were also required to have measurable disease with serum M-protein ≥0.5 g/dL and/or urine M-protein ≥200 mg/24-hour, or involved serum free light chain ≥ 10 mg/dL with abnormal kappa/lambda ratio. Additionally, participants had ECOG performance status of 0 or 1, absolute neutrophil count ≥  × 109/L, platelet count ≥ 50 ×109/L, creatinine clearance ≥ 60 ml/min and adequate cardiac and hepatic function among other inclusion criteria. The study excluded participants with known active or history of central nervous system involvement by MM, prior CAR T cell or another genetically modified T cell therapy, and prior therapy directed at BCMA.

Eligible participants underwent leukapheresis for collection of autologous T cells for product manufacturing. Participants received optional bridging therapy during the manufacturing period utilizing standard anti-myeloma drugs or combinations. Participants subsequently received lymphodepleting chemotherapy consisting of fludarabine 30 mg/m2/day and cyclophosphamide 300 mg/m2/day intravenously for 3 consecutive days, ending at least 2 (and a maximum of 9) days prior to infusion of BMS-986354. All participants were hospitalized for the first 14 days after BMS-986354 infusion and subsequently followed for 2 years for monitoring of toxicity and efficacy. After 2 years, participants were asked to participate in a long term follow up study (Study GC-LTFU-001).

Cytokine release syndrome (CRS) was graded according to criteria defined by Lee [13]. Other toxicities were graded utilizing the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

Ethics approval and consent to participate

The study was conducted in compliance with International Conference on Harmonization (ICH) and Good Clinical Practices (GCPs). The protocol was approved by the respective Institutional Review Board or ethics committee at each of the 10 participating institutions (University of Alabama at Birmingham, Birmingham, AL; Mount Sinai Health System, New York, NY; Mayo Clinic, Rochester, MN; Mayo Clinic Scottsdale, AZ; Atrium Health Levine Cancer Institute, Charlotte, NC; UT Southwestern Medical Center, Dallas, TX; University of Chicago, Chicago, IL, Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; all in the USA). All subjects provided documented informed consent. An independent Data Safety Monitoring Board (DSMB) periodically reviews data to ensure safety, scientific validity and integrity of the study. The decision regarding dose escalation or de-escalation was made by a Safety Review Committee (SRC) composed by investigators in collaboration with the Sponsor. This trial is registered on ClinicalTrials.gov as study NCT04394650.

Statistics

The study population consists of eligible participants infused with a conforming BMS-986354 product. Data are presented descriptively for each cohort in part A and for the expansion cohort in part B. Rates are described with 95% C.I. based on the exact binomial distribution. Secondary endpoints of duration of response (DOR), and PFS were analyzed utilizing the Kaplan-Meier method. The data cutoff for this analysis was June 16, 2023.

Pharmacokinetics

The vector copy number (VCN) was determined by a validated Digital Droplet Polymerase Chain Reaction (ddPCR) method to detect lentivirus gag sequence in a matrix of human genomic DNA, isolated from whole blood. The preliminary summary results at data cutoff of June 16, 2023, by dose level are presented as transgene copies per microgram of genomic DNA. Exposure at data cutoff of August 7, 2022, was also assessed by an exploratory method known as flow cytometry. PK parameters derived from results by flow cytometry such as Area Under the Curve from 0 to 28 days AUC0-28d, Maximum Concentration (Cmax), and Time to Maximum Concentration (Tmax) were calculated using non-compartmental analysis (Phoenix WinNonlin 8.3).

Drug product characterization

The memory phenotyping method is a flow based analytical method used to characterize the T cell memory composition and overall differentiation profile of the drug product by quantifying frequencies of bivariate populations including the following: CCR7 + CD45RA + , CCR7 + CD45RA-, CCR7-CD45RA-, and CCR7- CD45RA + .

The functionality of the drug product is assessed using the bulk cytokine release method, a multiplex assay that allows for the simultaneous measurement of multiple analytes in a single sample. The drug product is co-cultured overnight with the MM.1S cell line, which express BCMA endogenously. Upon incubation with the antigen-specific stimulated drug product, analytes/cytokines present will bind to their capture antibody and can be detected upon addition of a fluorescently labelled detection antibody. The reported concentration of each analyte in the test sample is determined relative to a standard curve generated with assay standards.

Results

Participants

There were 77 study participants enrolled between September 9, 2020, and August 24, 2022. Of those, 7 discontinued study participation after leukapheresis and before infusion of BMS-986354: 1 due to death, 2 due to disease progression, 1 due to withdrawal of consent, 1 due to failure to meet inclusion/exclusion criteria prior to lymphodepletion chemotherapy and 2 due to product manufacturing failure. One additional participant withdrew consent after initiating lymphodepleting chemotherapy and did not receive BMS-986354. Sixty-five participants (42 in dose escalation and 23 in dose expansion) were treated with conforming product and were the population of interest for safety and efficacy analyses (Fig. 1). In Part A, 7 participants were treated in DL1 (20 × 106 CAR + T cells), 24 in DL2 (40 × 106 CAR + T cells) and 11 in DL3 (80 × 106 CAR + T cells). Five participants had non-conforming products, of those 1 repeated apheresis and manufacturing and eventually received a conforming product. All 4 remaining participants received non-conforming products, 1 in DL2 and 3 in DL3. Most common reason for non-conformity was insufficient number of CAR T-cells for the respective dose level (yet meeting or exceeding prior dose level with acceptable safety and efficacy).

Fig. 1: Consort diagram showing disposition of all participants enrolled in the study.
figure 1

*Participant chose to repeat leukapheresis and initiate new manufacturing. #Preceded by disease progression. LDC lymphodepleting chemotherapy.

Full size image

Characteristics of participants are displayed in Table 1. Participants enrolled after a median of 6.3 (0.7–24.6) years from diagnosis and 5 (3–13) prior myeloma regimens. Median age at treatment was 63 (43-75) years, 25 (39%) had myeloma harboring high-risk chromosome abnormalities (17p13 deletion, 17p del, t4;14, or t14;16), and 28 (43%) had extramedullary plasmacytomas. Fifty-nine (91%) participants had triple-class (PI, IMiD and anti-CD38 monoclonal antibody) refractory MM and 31 (48%) had penta-drug (lenalidomide, pomalidomide, bortezomib, carfilzomib and daratumumab) refractory MM. Thirty-eight (59%) of participants were treated with optional bridging therapy between leukapheresis and lymphodepletion.

Table 1 Patient, disease, and prior treatment characteristics.
Full size table

Safety

During part A, none of the 7 participants treated in DL1 experienced a DLT, 4 of 24 (16.7%) participants in DL2 (prolonged neutropenia and thrombocytopenia [n = 1], prolonged neutropenia [n = 2], decreased fibrinogen [n = 1]), and 3 of 11 (27.3%) participants in DL3 developed a DLT (prolonged neutropenia [n = 2], prolonged thrombocytopenia [n = 1]). All 3 dose levels were declared tolerable per pre-specified criteria. The SRC, considering safety, efficacy, PK and PD data, chose DL2 (40 × 106 CAR + T cells) as the RP2D to expand in Part B.

All participants developed at least one treatment-emergent adverse event, irrespective of attribution. Fifty-three (82%) participants developed CRS, all grade 1 or 2 except for a single episode of grade 4 CRS in a participant in Part B. Median time between BMS-986354 infusion and onset of CRS was 4 (1–8) days, and median duration of CRS was 4 (1–9) days. There was no clear change in incidence, time of onset, duration, or severity of CRS with higher doses of BMS-986354 (Table 2). Treatments for CRS included tocilizumab in 48 (74%), dexamethasone in 31 (48%) and anakinra in 10 (15%) participants. Five (8%) participants experienced neurological toxicity events consisting with ICANS, 4 were grade 1, and 1 was grade 4. Median time of onset for neurotoxicity/ICANS was 5 (range 5–9) days and episodes lasted a median of 3 (range 1–12) days, requiring treatment with glucocorticoids in 3 (5%) participants. None of the participants developed cranial nerve palsy or Parkinsons-like symptoms (Table 3).

Table 2 Immune effector-mediated toxicities of special interest.
Full size table
Table 3 Treatment-emergent adverse events occuring in 20% or more of participants.
Full size table

The most common treatment-emergent adverse events were hematologic, developing in 57 (88%) of participants, including 50 (76%) participants with neutropenia and 32 (49%) with thrombocytopenia. Grades 3/4 neutropenia and thrombocytopenia occurred in 48 (74%) and 25 (39%) participants respectively. Twenty-one participants (32%) developed infections, including 5 (7.7%) with grades 3/4 infections. Treatment-emergent adverse events occurring in at least 20% of participants are displayed in Table 3. There were no apparent differences in toxicity profile across different dose levels tested.

Two participants developed non-melanoma skin cancer (one basal cell, one squamous cell carcinoma). Three participants developed myelodysplastic syndrome (MDS). In the first case the patient had a newly demonstrated loss of chromosome 5q in the bone marrow sample obtained 1 month after BMS-986354. The patient developed progression of MM 12 months after treatment and received subsequent anti-MM therapy; subsequent analysis revealed expansion of the abnormal myeloid clone and additional cytogenetic abnormalities. In the second case, the patient developed MDS not otherwise specified 6 months after BMS-986354. There were no chromosome abnormalities and a next generation sequencing mutational panel revealed mutations in TP53; it is unknown if such mutations were present prior to BMS-986354. The third patient developed MDS 11 months after infusion of BMS-986354. Chromosome abnormalities identified included del(7q), del(5q). All 3 patient were alive at time of last follow up.

Efficacy

Fast and deep responses were seen in all dose levels; 62 (95%, 95% C.I. 87%–99%) participants had partial response (PR) or better (PR, very good partial response, and CR/sCR), and 30 (46%, 95% C.I. 34%–59%) had CR/sCR. For the 47 participants treated at the RP2D, 44 (94%, 95% C.I. 82%–99%) had PR or better and 18 (38%, 95% C.I. 25%–54%) had CR/sCR (Table 4). Median time to response was 1.0 (range 0.9–4.1) month. Among the participants with PR or better, median duration of response was 11.3 (95% C.I. 10.6–17.1) months and 15.1 (95% C.I. 11.0-NE) months for participants who achieved CR/sCR (Fig. 2). Among the participants with PR or better, median follow time was 10.15 (1.0–18.7) months and 11.86 (4.6–18.7) months for participants who achieved CR/sCR. There were 25 participants with disease progression in Part A, and 10 in Part B. All (n = 5) deaths in Part A and Part B (N = 47) were preceded by disease progression. Median PFS was 12.3 months (95% C.I. 11.3–16.0) for all participants and 11.9 months (95% C.I. 9.2–18.0) for participants treated at the RP2D (Fig. 3).

Fig. 2: Depth and duration of response to BMS-986354.
figure 2

Swimmers’ plot displaying response trajectories for individual participants participants in each cohort.

Full size image
Fig. 3: Progression-free survival of participants treated with BMS-98654.
figure 3

Kaplan-Meier curve displaying progression free survival for participants treated with BMS-98654 at the recommended phase 2 dose (RP2D).

Full size image
Table 4 Anti-myeloma activity of BMS-986354.
Full size table

Product manufacturing and characteristics

Orva-cel and BMS-98654 are transduced with the identical CAR construct, however, orva-cel is manufactured using a conventional, fully expanded process, whereas BMS-98654 is manufactured using an optimized NEX-T® process [10]. Multiple factors beyond manufacturing affect apheresis to infusion (“vein-to-vein”) in the context of a clinical trial, including post manufacturing quality control, staggering of subjects during dose-finding phase, recovery after bridging therapy, among others. Median time from apheresis to product availability was 30 days, median time from product availability to BMS-98654 infusion was 16 days and median time from apheresis to product infusion (“vein-to-vein”) was 45 days. Preliminary pharmacokinetic analysis using ddPCR showed robust in-vivo expansion at all dose levels (Fig. 4, panel A) with maximal expansion in approximately the first 2 weeks and persistence of detectable CAR T cells beyond 6 months after infusion. BMS-986354 at dose of 40 × 106 CAR T cells produced similar Cmax and similar AUC0-28d derived using flow cytometry to orva-cel at approximately 10 times higher of a dose (450 × 106 CAR T cells), demonstrating approximately tenfold increased proliferative capacity and potency on a cell-by-cell basis (Fig. 4, panel B).

Fig. 4: Pharmacokinetics of BMS-98654.
figure 4

BMS-986354 expansion and persistence at different dose levels as assessed by digital droplet polymerase chain reaction (A). Comparison of pharmacokinetic parameters between BMS-986354 at dose of 40 × 106 CAR T cells and orva-cel at dose of 450 × 106 CAR T cells (B), as assessed by flow cytometry. The error bars on panel A indicate interquartile range (IQR). The error bars on panel B indicate 95% CI of the mean. DL dose level, AUC0–28 Geometric mean area under the curve of the transgene level from time of dose to 28 days after infusion, Cmax geometric mean maximum blood concentration.

Full size image

Complete phenotypic characterization of 65 BMS-98654 products was compared with characteristics of 71 orva-cel products [10]. In the CD4 compartment, BMS-986354 cells had a higher proportion of a central memory phenotype (TCM, CCR7 + CD45RA-, 83% vs. 53%) and a lower proportion of effector memory phenotype (TEM, CCR7-CD45RA-, 4% vs 23%). Similarly, in the CD8 compartment 58% (vs. 40%) of cells were TCM, and 4% (vs. 13%) were TEM (Fig. 5, panel A). When stimulated with MM.1S, which endogenously express BCMA, BMS-986354 secretes higher amounts of INFg, IL-2 and TNFa than orva-cel (Fig. 5, panel B).

Fig. 5: Phenotypic comparison of BMS-98654 and orva-cel.
figure 5

BMS-986354 exhibits a higher proportion of central memory and a lower proportion of effector memory and TEMRA in both CD4 and CD8 compartments (A). Following stimulation, BMS-98654 exhibits enhanced INFγ, IL-2 and TNFα when compared to orva-cel (B). Immune markers: naive-like, CCR7 + CD45RA + ; Central Memory CCR7 + CD45RA-; Effector Memory, CCR7-CD45RA- T effector memory RA (TEMRA), CD45RA + CCR7-. ****P ≤ 0.0001. IFNγ interferon gamma, IL-2 interleukin-2, TNFα tumor necrosis factor alpha.

Full size image

Discussion

BMS-986354 is a fully humanized anti-BCMA autologous CAR T cell therapy produced using an optimized NEX-T® process. In the present first-in-human phase 1 trial, we demonstrate a robust manufacturing process, reduced manufacturing time, improved phenotypic attributes with enrichment for central memory cells, and greater antigen-specific cytokine production when compared to orva-cel, despite the same CAR construct. An infusion of BMS-986354 leads to CAR T expansion and persistence similar to orva-cel when administered at a 10 times lower dose, demonstrating enhanced potency and proliferative capacity on a cell-by-cell basis. Persistence of whole blood concentration derived using ddPCR was up to 720 days (i.e. 24 months) post BMS-986354 dose at the highest nominal dose level of 80 million.

Long term disease control may be directly related to in vivo persistence of CAR T cells [14, 15]. In multiple studies, higher percentage of central memory T cells positively correlated with superior antitumor efficacy and better long-term disease control [14, 16]. The proliferative capacity of T cells is impacted by their state of differentiation. Stem cell-like memory T cells (TSCM), which are less differentiated, have increased potential to renew, replicate and generate all T cell subtypes including central memory (TCM) and effector memory (TEM) cells [17]. Unlike TCM cells which can self-renew, TEM are short lived and are responsible for early immune response [18] which correlates with potential for toxicity with adoptive immunotherapy and lacks the ability to sustain responses [18, 19]. CAR T cells undergo progressive differentiation after infusion, losing their proliferative capacity [20]. BMS-986354, with higher percentage of memory phenotype, offers a potentially efficacious CAR T manufacturing platform with a favorable safety profile. While low grade CRS was common, grade 3 or higher CRS was rare, seen only in 1 (2%) participant. For context, grade 3 CRS was seen in 5% of participants treated with ide-cel [4], 4% of participants treated with cilta-cel in the CARTITUDE-1 trial [5], and 35% of participants treated with cilta-cel in the CARTIFAN-1 trial [21]. Neurotoxicity occurred in 5 (8%) participants, all except for 1 were grade 1 and resolved in all. In contrast, neurotoxicity occurred in 18% of participants receiving ide-cel (including 3% grade 3) [4], 21% of participants receiving cilta-cel in CARTITUDE-1 (9% grade 3) [5]. None of the BMS-986354 recipients developed cranial nerve abnormalities or parkinsonism like neurologic complications. Infections were seen in 32% of participants, the majority were grades 1 or 2, and no deaths related to infection were noted. Cytopenias were common as anticipated (77% neutropenia and 49% thrombocytopenia) but prolonged neutropenia beyond 90 days was rare (5 participants, 8%). There were no deaths related to BMS-986354 toxicity. The maximal tolerated dose of BMS-986354 was not exceeded, and the study was expanded at the intermediate dose of 40 × 106 cells. In aggregate, the safety of BMS-986354 compares favorably to available BCMA-directed CAR T cell therapies [4, 5, 21].

BMS-986354 had a high rate of responses (95%) including deep response (46% CR) in a cohort with a high percentage of patients with extramedullary disease (43%) and high-risk cytogenetic abnormalities (39%). Responses were comparable to orva-cel at higher doses with ORR of 91% and 40% CR rates [10]. Responses following BMS 986534 infusion were rapid, with median time to response of 1.0 month and sustained with median DOR of 11.3 months (95% C.I. 10.6–17.1). Increased depth of response correlated with durability of response, with median DOR of 15.1 months (95% C.I. 11.0-NE) for participants who achieved CR. There was no clear difference in depth or duration of response across the doses tested. The anti-myeloma activity of BMS-986354 compares favorably with historical results of conventional therapy in participants with triple-class exposed MM with response rates ~30% and median PFS < 5 months as shown in the observational MAMMOTH [22] and LOCOMMOTION [23] studies and in the control arm of the recent KARMMA-3 trial [24]. In fact, anti-myeloma activity compares favorably with other approved BCMA-directed therapy including CAR T cell [4] and bispecific T cell engagers [2, 3]. The overall response rate seen with BMS-986354 approaches what is reported with cilta-cel in the CARTITUDE-1 study in similar participant population, yet depth and duration of responses were numerically inferior [25].

The present study provides clinical validation that the NEX-T® process enables reliable manufacturing of an optimally expanded CAR T cell product with improved phenotypic characteristics, robust in-vivo expansion, and potent anti-myeloma effect when administered at low doses. BMS-986354 exhibited a tolerable safety profile, with only a single participant experiencing Grade 3 CRS or NT in a population with heavily pre-treated RRMM. While BMS-986354 is not currently being further developed, these results highlight the potential of the NEX-T® manufacturing process in future CAR T clinical development.

Related Articles

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who have received at least 4 prior lines of therapy, based on response rates observed in DREAMM-1/DREAMM-2. Despite the 41% response rate and durable responses observed with belantamab mafodotin in the Phase III confirmatory DREAMM-3 trial, the marketing license for belantamab mafodotin was later withdrawn from US and European markets when the trial did not meet its primary endpoint of superiority for progression-free survival compared with pomalidomide and dexamethasone. This review reflects on key lessons arising from the clinical journey of belantamab mafodotin in RRMM. It considers how incorporating longer follow-up in DREAMM-3 may have better captured the clinical benefits of belantamab mafodotin, particularly given its multimodal, immune-related mechanism of action with responses deepening over time. A non-inferiority hypothesis may have been more appropriate rather than superiority in the context of a monotherapy versus an active doublet therapy. Further, anticipation of, and planning for, non-proportional hazards arising from response heterogeneity may have mitigated loss of statistical power. With the aim of improving the efficacy of belantamab mafodotin, other Phase III trials in the RRMM development program (DREAMM-7 and DREAMM-8) proceeded to evaluate the synergistic potential of combination regimens in earlier lines of treatment. The aim was to increase the proportion of patients responding to belantamab mafodotin (and thus the likelihood of seeing a clear separation of the progression-free survival curve versus comparator regimens). Protocol amendments reflecting DREAMM-3 learnings could also be implemented prospectively on the combinations trials to optimize the follow-up duration and mitigate risk. The wider implications of the lessons learned for clinical research in RRMM and in earlier treatment settings are discussed.

The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors

We investigated a novel cancer immunotherapy strategy that effectively suppresses tumor growth in multiple solid tumor models and significantly extends the lifespan of tumor-bearing mice by introducing pathogen antigens into tumors via mRNA-lipid nanoparticles. The pre-existing immunity against the pathogen antigen can significantly enhance the efficacy of this approach. In mice previously immunized with BNT162b2, an mRNA-based COVID-19 vaccine encoding the spike protein of the SARS-CoV-2 virus, intratumoral injections of the same vaccine efficiently tagged the tumor cells with mRNA-expressed spike protein. This action rapidly mobilized the pre-existing memory immunity against SARS-CoV-2 to kill the cancer cells displaying the spike protein, while concurrently reprogramming the tumor microenvironment (TME) by attracting immune cells. The partial elimination of tumor cells in a normalized TME further triggered extensive tumor antigen-specific T cell responses through antigen spreading, eventually resulting in potent and systemic tumor-targeting immune responses. Moreover, combining BNT162b2 treatment with anti-PD-L1 therapy yielded a more substantial therapeutic impact, even in “cold tumor” types that are typically less responsive to treatment. Given that the majority of the global population has acquired memory immunity against various pathogens through infection or vaccination, we believe that, in addition to utilizing the widely held immune memory against SARS-CoV-2 via COVID-19 vaccine, mRNA vaccines against other pathogens, such as Hepatitis B Virus (HBV), Common Human Coronaviruses (HCoVs), and the influenza virus, could be rapidly transitioned into clinical use and holds great promise in treating different types of cancer. The extensive selection of pathogen antigens expands therapeutic opportunities and may also overcome potential drug resistance.

Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation

Immune effector cells, including cytotoxic T lymphocytes (CTLs) play essential roles in eliminating cancer cells. However, their functionality is often compromised, even when they infiltrate the tumor microenvironment (TME) or are transferred to cancer patients adoptively. In this study, we focused on galectin 9 (G9), an inhibitory ligand that we observed to be predominately positioned on the plasma membrane and readily interacts with CD8 + CTL in the TME of nasopharyngeal carcinoma (NPC). We discovered that cell-cell contact between activated effector CTLs and target tumor cells (TarTC) with G9 overexpression led to cellular death defects. Despite the formation of CTL–TarTC conjugates, there is no impact on the cell number nor viability of CTL, and the release of cytolytic content and associated activity were not completely abrogated. Instead, this interaction promoted autophagy and restricted necrosis in the TarTC. Furthermore, reducing G9 expression in tumor cells enhanced the suppressive effect on tumor growth upon adoptive transfer of activated effector CTL. Additionally, inhibiting autophagy effectively controlled tumor growth in cases of G9 overexpression. Therefore, we highlight the contribution of G9 in facilitating the resistance of NPC to CTL-mediated killing by inducing a selection-cell death state in tumor cells, characterized by increased autophagy and decreased necrosis.

Responses

Your email address will not be published. Required fields are marked *